T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

  • Interventional
  • Not Recruiting
  • NCT00683046
Eligibility Details Visit Clinicaltrials.gov

T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies

Objectives: 1. To evaluate disease free survival after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies. 2. To evaluate the incidence and severity of acute and chronic GVHD after Campath 1H-based in vivo T-cell depletion, in patients with hematologic malignancies undergoing non-myelo-ablative stem cell transplantation. 3. To evaluate engraftment and chimerism after Campath 1H-based in vivo T-cell depletion and non-myelo-ablative ablative stem cell transplantation in patients with hematologic malignancies.

Gender
All

Age Group
100 Years and under

Accepting Healthy Volunteers?
No

Inclusion Criteria:

         - Zubrod performance status 2 (See Appendix B).

         - Life expectancy is not severely limited by concomitant illness.

         - Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol.

         - Serum creatinine <1.5 mg/dL or Creatinine Clearance >50 ml/min .

         - Serum bilirubin 2.0 mg/dl, SGPT <3 x upper limit of normal

         - No evidence of chronic active hepatitis or cirrhosis.

         - HIV-negative

         - Patient is not pregnant

         - Patient or guardian able to sign informed consent.

        Exclusion Criteria:

         - N/A

At a Glance

National Government IDNCT00683046

IRB#11300A

Lead SponsorUniversity of Chicago

Lead PhysicianHongtao Liu

Collaborator(s)N/A

EligibilityAll
100 Years and under
Not Recruiting